| Name | Title | Contact Details |
|---|
University Hospitals, one of the nation`s leading health care systems, focuses on providing compassionate, quality medical care to patients at convenient locations throughout Northeast Ohio.
OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, we have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of our pipeline. The assay is based on examining specific transcription levels between phagocytic and non-phagocytic cells. This proprietary technology and algorithm has allowed us to not only detect disease but to also, and more importantly, guide the physician as to the grade and aggressiveness of the disease. Our mission is to provide clinicians with quantifiable results that allows professionals to make timely and much more directed medical decisions.
Microtek Medical is also a prominent contract manufacturer serving as the OEM for some of the medical world's best known brands. So, whether under the Microtek name or bearing another corporate label, Microtek produces a large volume of the products now
FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs. FibroGen’s research team is committed to discovering novel therapies in areas of major unmet medical need. Our goal is to continue to provide pipeline candidates supported by rigorous data in well-characterized therapeutic settings. All of FibroGen`s therapeutic candidates have been internally developed based on FibroGen`s pioneering research in two important areas of biology, hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF).
Crouse Hospital has been caring for generations of Central New Yorkers since 1887. Our mission is to provide the best in patient care by exceeding the expectations of our patients and to promote community health. A private, not-for-profit hospital, Crouse is licensed for 506 acute-care beds and 57 bassinets. We serve more than 23,000 inpatients, 66,000 emergency services patients and more than 250,000 outpatients a year from a 15-county area in Central and Northern New York.